Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders

Putte, Dietje E. Fransen van de; Makris, Michael; Fischer, Kathelijn; Yee, T. T.; Kirk, Lisa; Erpecum, Karel J. van; Patch, David; Posthouwer, D.; Mauser‐Bunschoten, Eveline P.

doi:10.1016/j.jhep.2013.08.010

Cited by 51 publications

(109 citation statements)

References 39 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…In our cohort of 71 elderly patients, HIV did not occur and chronic hepatitis B and C infections were rare, but higher than in the general population, with a prevalence of 0.4% and 0.002%, respectively [33,34]. This is in contrast to elderly hemophilia patients [11,35], in whom the prevalence of HIV infections ranges from 3.5% to 13%, and that of hepatitis C infections ranges from 69% to 92% [30,36]. Although some patients may have died before inclusion, most VWD patients probably received less factor-replacement therapy than hemophilia patients, and therefore suffered fewer transfusion-transmitted viral infections [37].…”

Section: Discussionmentioning

confidence: 73%

von Willebrand disease and aging: an evolving phenotype

Sanders

Giezenaar

Gorkom

et al. 2014

Journal of Thrombosis and Haemostasis

136

View full text Add to dashboard Cite

Summary. Background: Because the number of elderly von Willebrand disease (VWD) patients is increasing, the pathophysiology of aging in VWD has become increasingly relevant. Objectives: To assess age-related changes in von Willebrand factor (VWF) and factor VIII (FVIII) levels and to compare age-related differences in bleeding phenotype between elderly VWD patients and those < 65 years. We also studied co-morbidity in elderly patients. Patients/ Methods: We included VWD patients with VWF levels ≤ 30 U dL À1 in the nationwide cross-sectional 'Willebrand in the Netherlands' (WiN-) study. Patients reported bleeding episodes and treatment of VWD in the year preceding inclusion and during life. This was compared between VWD patients older (n = 71) and younger (16-64 years, n = 593) than 65 years. In elderly patients, agerelated changes in VWF and FVIII levels were studied longitudinally by including all historically measured levels. All medical records were examined for co-morbidity. Results: In elderly type 1 patients, a decade age increase was associated with a 3.5 U dL À1 (95% CI, À0.6 to 7.6) VWF:Ag increase and 7.1 U dL À1 (95% CI, 0.7 to 13.4) FVIII:C increase. This increase was not observed in elderly type 2 patients. Elderly type 2 patients reported significantly more bleeding symptoms in the year preceding inclusion than younger patients (16/27, 59% vs. 87/ 221, 39%; P = 0.048), which was not observed in type 1 VWD. Conclusions: von Willebrand factor parameters and bleeding phenotype evolve with increasing age in VWD. VWF and FVIII levels increase with age in type 1 patients with no mitigation in bleeding phenotype. In type 2 patients VWF parameters do not increase with age and in these patients aging is accompanied by increased bleeding.

show abstract

Section: Discussionmentioning

confidence: 73%

von Willebrand disease and aging: an evolving phenotype

Sanders

Giezenaar

Gorkom

et al. 2014

Journal of Thrombosis and Haemostasis

136

View full text Add to dashboard Cite

show abstract

“…Before effective and universal screening of blood and blood‐derived clotting factors, almost all patients with inherited blood disorders (IBLDs), including those with hemoglobinopathies such as sickle cell disease and β‐thalassemia or clotting factor deficiencies such as hemophilia and von Willebrand disease, were also infected with the hepatitis C virus (HCV) . Patients with IBLDs are living longer attributable to improvements in their specialized medical care, but remain at risk for the significant morbidity and mortality (such as end‐stage liver disease and hepatocellular carcinoma) associated with HCV infection . While improvements in blood banking procedures have led to almost no transfusion‐associated HCV infections in Western countries, HCV‐contaminated blood products continue to contribute new cases of HCV infection in resource‐constrained settings …”

mentioning

confidence: 99%

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It is well recognized that HIV coinfection accelerates HCV-related liver disease; thus, a large number of hemophilia patients develop ESLD, which accounts for 10% of liver transplantations for HCV/HIV-coinfected patients. 1 With the advances in antiretroviral therapy (ART) in the mid-1990s and the improved outcome of HIV-infected patients, the indication for liver transplantation in ESLD patients with HCV/HIV coinfection is almost the same as that for HCV-monoinfected patients in all centers worldwide. Liver transplantation for hemophilia patients with ESLD due to HCV cures not only the liver failure but also coagulation abnormalities, making lifelong clotting factor replacement unnecessary.…”

mentioning

confidence: 99%